MedTrace Logo

Subcutaneous-Sublingual Immunotherapy With Depigmented and Polymerized Dermatophagoides Pteronyssinus Allergen Extract

NCT00622362 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 3

Last updated 2019-03-08

No results posted yet for this study

Summary

The objective of this trial is to evaluate the clinical effectiveness of the administration of a depigmented and polymerized allergen extract Dermatophagoides pteronyssinus in children with allergic asthma due to this mite

Conditions

  • Allergic Asthma

Interventions

BIOLOGICAL

DEPIGOID Dermatophagoides pteronyssinus

Subcutaneous administration:0.5 ml/month during 1 year

BIOLOGICAL

Polymerized TOL of Dermatophagoides pteronyssinus

Sublingual immunotherapy. Two drops daily during 1 year

BIOLOGICAL

Placebo Comparator

Sublingual immunotherapy. Two drops daily during 1 year

Sponsors & Collaborators

  • Laboratorios Leti, S.L.

    lead INDUSTRY

Principal Investigators

  • Antonio Nieto, MD PhD

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
5 Years
Max Age
14 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-01-31
Primary Completion
2009-02-28
Completion
2009-02-28

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00622362 on ClinicalTrials.gov